Correlation Engine 2.0
Clear Search sequence regions

  • brain (1)
  • glia (2)
  • impaired (2)
  • investigates (1)
  • locomotor activity (5)
  • minor (1)
  • motor activity (1)
  • neuroglia (2)
  • neuron (4)
  • rats (4)
  • serotonin (1)
  • Sizes of these terms reflect their relevance to your search.

    Cerebral palsy (CP) is characterized by motor disorders, including deficits in locomotor activity, coordination, and balance. Selective serotonin reuptake inhibitors have been shown to play an important role in brain plasticity. This study investigates the effect of neonatal treatment using fluoxetine on locomotor activity and histomorphometric parameters of the primary somatosensory cortex (S1) in rats submitted to an experimental model of CP. CP was found to reduce bodyweight and locomotion parameters and also to increase the glia/neuron index in the S1. Administration of fluoxetine 10 mg/kg reduced bodyweight, impaired locomotor activity parameters, and increased the number of glial cells and the glia/neuron ratio in the S1 in rats with CP. However, treatment with fluoxetine 5 mg/kg was not found to be associated with adverse effects on locomotor activity and seems to improve histomorphometric parameters by way of minor changes in the S1 in animals with CP. These results thus indicate that experimental CP, in combination with the use of a high dose of fluoxetine (10 mg/kg), impairs locomotor and histomorphometric parameters in the S1, while treatment with a low dose of fluoxetine (5 mg/kg) averts the negative outcomes associated with a high dose of fluoxetine in relation to these parameters but produces no protective effect.


    Glayciele Leandro de Albuquerque, Raul Manhães-de-Castro, Diego Cabral Lacerda, Caio Matheus Santos da Silva Calado, André Teracio Bezerra de Morais, Diego Bulcão Visco, Francisco Machado Manhães-de-Castro, Ana Elisa Toscano. Neonatal treatment with fluoxetine alters locomotor activity and the cortical glial/neuron index in rats with cerebral palsy. Canadian journal of physiology and pharmacology. 2023 Jul 01;101(7):327-339

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36988145

    View Full Text